• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Erasca Inc.

    4/29/25 4:28:47 PM ET
    $ERAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ERAS alert in real time by email
    DEFA14A 1 d902108ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.  )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    Erasca, Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     
     


      LOGO

     

      P.O. BOX 8016, CARY, NC 27512-9903

     

    LOGO

       LOGO

    Erasca, Inc.

     

    Annual Meeting of Stockholders

     

    Tuesday, June 24, 2025 11:30 AM, Pacific Time

     

    Annual Meeting to be held live via the internet - please visit www.proxydocs.com/ERAS for more details

     

    You must register to attend the meeting online and/or participate at www.proxydocs.com/ERAS

     

     

    For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to www.proxydocs.com/ERAS

     

    To vote your proxy while visiting this site, you will need the 12 digit control number in the box below.

     

    This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting.

     

    Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the internet.

     

    If you want to receive a paper or e-mail copy of the proxy material, you must request one. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before June 13, 2025.

           

     

     

    Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report or Form 10-K

     

    Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On June 24, 2025 For Stockholders of record as of April 28, 2025

     

    To order paper materials, use one of the following methods.

     

      LOGO

     

    Internet:

    www.investorelections.com/ERAS

     

      LOGO

    Call:

    1-866-648-8133

     

      LOGO

    Email:

    [email protected]

     

    * If requesting material by e-mail, please send a blank e-mail with the 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your e-mail requesting material.

           

     

    LOGO

      
         

    Have the 12 digit control number located in the box above available when you access the website and follow the instructions.

    SEE REVERSE FOR FULL AGENDA      

    Copyright © 2025 BetaNXT, Inc. or its affiliates. All Rights Reserved   


    LOGO   Erasca, Inc. Annual Meeting of Stockholders

    THE BOARD OF DIRECTORS RECOMMENDS A VOTE:

       FOR ON PROPOSALS 1 AND 2

     

     

     

    PROPOSAL

     

    1.    To elect three directors to serve as Class I directors for a three-year term expiring at the 2028 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified   
       1.01 Jonathan E. Lim, M.D.   
       1.02 James A. Bristol, Ph.D.   
       1.03 Valerie Harding - Start, Ph.D.   
    2.    To ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025   
    3.    To transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment of the Annual Meeting
    Get the next $ERAS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ERAS

    DatePrice TargetRatingAnalyst
    3/26/2025$5.00Outperform
    Raymond James
    11/18/2024$6.00Buy
    Jefferies
    3/11/2024$8.00Overweight
    CapitalOne
    1/5/2024$11.00 → $6.00Buy → Neutral
    BofA Securities
    10/11/2023$10.00Buy
    H.C. Wainwright
    3/30/2023$9.00Buy
    Mizuho
    2/24/2023$10.00Buy
    Goldman
    2/3/2023$15.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $ERAS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Erasca Reports First Quarter 2025 Business Updates and Financial Results

      Early entry of RAS-targeting franchise into clinic enabled by strong execution Initial Phase 1 monotherapy data for pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 expected in 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $411 million as of March 31, 2025 with cash runway guidance extended to H2 2028 SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter ended M

      5/13/25 4:05:00 PM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Erasca Announces Early Clinical Advancement and Prioritization of RAS-Targeting Franchise Coupled with More than 3 Years of Projected Cash Runway

      IND cleared for pan-RAS molecular glue ERAS-0015 and IND submitted for pan-KRAS inhibitor ERAS-4001, both ahead of schedule; Phase 1 monotherapy data for both programs expected in 2026 Meaningful extension of cash runway guidance from H2 2027 to H2 2028 following strategic decision to pursue partnership opportunities for naporafenib SAN DIEGO, May 13, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced clearance of an investigational new drug (IND) application by the United States Food and Drug Admini

      5/13/25 8:00:00 AM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Erasca to Present at the Bank of America Securities Health Care Conference

      SAN DIEGO, May 07, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Securities 2025 Health Care Conference being held at the Encore Hotel in Las Vegas, Nevada. Management will present on Wednesday, May 14, 2025, at 2:35 pm Pacific Time and will also participate in one-on-one investor meetings. A live audio webcast of the event will be available online at Erasca.com/events. An archived replay of the event will be available for 30 days following the webcast at E

      5/7/25 8:00:00 AM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ERAS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James initiated coverage on Erasca with a new price target

      Raymond James initiated coverage of Erasca with a rating of Outperform and set a new price target of $5.00

      3/26/25 7:49:37 AM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Erasca with a new price target

      Jefferies initiated coverage of Erasca with a rating of Buy and set a new price target of $6.00

      11/18/24 7:43:18 AM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CapitalOne initiated coverage on Erasca with a new price target

      CapitalOne initiated coverage of Erasca with a rating of Overweight and set a new price target of $8.00

      3/11/24 7:50:07 AM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ERAS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by General Counsel & Corp. Sec. Garner Ebun

      4 - Erasca, Inc. (0001761918) (Issuer)

      2/18/25 9:00:03 AM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CFO and CBO Chacko David M. acquired $24,181 worth of shares (15,461 units at $1.56), increasing direct ownership by 1% to 262,187 units (SEC Form 4)

      4 - Erasca, Inc. (0001761918) (Issuer)

      2/5/25 9:24:43 AM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Medical Officer Morris Shannon

      4 - Erasca, Inc. (0001761918) (Issuer)

      2/5/25 9:20:22 AM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ERAS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Casdin Alexander W. bought $181,920 worth of shares (80,000 units at $2.27) (SEC Form 4)

      4 - Erasca, Inc. (0001761918) (Issuer)

      5/22/24 6:57:45 PM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Start Valerie Denise Harding bought $18,480 worth of shares (10,000 units at $1.85) (SEC Form 4)

      4 - Erasca, Inc. (0001761918) (Issuer)

      12/8/23 9:10:12 AM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lim Jonathan E bought $1,696,179 worth of shares (1,000,000 units at $1.70) (SEC Form 4)

      4 - Erasca, Inc. (0001761918) (Issuer)

      12/6/23 7:41:47 PM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ERAS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Erasca Inc.

      SC 13G/A - Erasca, Inc. (0001761918) (Subject)

      11/14/24 5:13:04 PM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Erasca Inc.

      SC 13G/A - Erasca, Inc. (0001761918) (Subject)

      11/14/24 4:04:32 PM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Erasca Inc.

      SC 13G - Erasca, Inc. (0001761918) (Subject)

      11/14/24 1:28:34 PM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ERAS
    Leadership Updates

    Live Leadership Updates

    See more
    • Erasca Appoints Jean Liu to its Board of Directors

      SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Jean Liu to its board of directors and to its audit committee. Ms. Liu brings over 20 years of professional experience advising biopharmaceutical companies on corporate, intellectual property, compliance, and general legal matters. "Jean Liu has been a seasoned executive with Seagen during its transformation into a leading global, multiproduct oncology company, and she also is one of the most strategic busine

      4/27/22 8:00:00 AM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Erasca Strengthens Leadership Team with Two Key Executive Appointments

      Lisa Tesvich-Bonora appointed as Chief People Officer Robert Shoemaker promoted to Senior Vice President of Research SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Lisa Tesvich-Bonora as Chief People Officer and the promotion of Robert Shoemaker to Senior Vice President of Research. "I am thrilled to welcome Lisa to the Erasca family. With over two decades of experience in creating collaborative and engaging environments where employees can thrive, she bring

      1/18/22 8:00:00 AM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ERAS
    Financials

    Live finance-specific insights

    See more

    $ERAS
    SEC Filings

    See more
    • Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise

      Pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 are potent, oral inhibitors with potential best-in-class profiles in RASm solid tumors Pipeline prioritization and workforce restructuring sharpens focus on programs targeting the highest unmet needs and with highest probability of success Priced concurrent $160 million equity offering Erasca to host conference call and webcast Friday, May 17, 2024 at 8:30 am ET SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today anno

      5/16/24 8:02:00 PM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Erasca Reports First Quarter 2024 Business Updates and Financial Results

      Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma Strengthened balance sheet with private placement financing from high-quality new and existing healthcare-focused investors Pro forma cash, cash equivalents, and marketable securities of $334 million is expected to fund operations into H2 2026 SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter ended March

      5/8/24 4:01:00 PM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results

      Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS-007, and ERAS-801 Multiple data readouts expected in 2024 for naporafenib (SEACRAFT-1), ERAS-007 (HERKULES-3), and ERAS-801 (THUNDERBBOLT-1) and planned initiation of pivotal SEACRAFT-2 trial Robust balance sheet with cash, cash equivalents, and marketable securities of $322 million as of December 31, 2023 Erasca to host R&D update conference call and webcast Thursday, March 28, 2024 at 8:30 am ET SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and comm

      3/27/24 4:01:00 PM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Erasca Inc.

      10-Q - Erasca, Inc. (0001761918) (Filer)

      5/13/25 4:24:15 PM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Erasca Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Erasca, Inc. (0001761918) (Filer)

      5/13/25 4:10:10 PM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Erasca Inc.

      DEFA14A - Erasca, Inc. (0001761918) (Filer)

      4/29/25 4:28:47 PM ET
      $ERAS
      Biotechnology: Pharmaceutical Preparations
      Health Care